Hematological toxicity of doxorubicin-containing protocols in dogs with spontaneously occurring malignant tumors.
The medical records of 49 dogs with spontaneously occurring malignant tumors treated with doxorubicin-based chemotherapy protocols were evaluated for hematological toxicity. Protocols included vincristine, doxorubicin, and cyclophosphamide (VAC); 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC); doxorubicin and cyclophosphamide (AC); and doxorubicin and dacarbazine (ADIC). Prevalence of Grades 1, 2, or 3 toxicities were less than 30%, and the prevalence of Grade 4 toxicity alone was less than 5%. The frequency of sepsis was less than 2.5% in dogs treated with VAC, FAC, or AC, and it was 15% in dogs treated with ADIC. There were no significant differences in the prevalence or severity of hematological toxicity caused by VAC or AC. Five-fluorouracil, doxorubicin, and cyclophosphamide caused significantly more severe neutropenia than VAC or AC. The low prevalence of hematological complications makes these protocols acceptable for use in practice.
Ahaus
E A
EA
Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus 43210, USA.
Couto
C G
CG
Valerius
K D
KD
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D007958:Leukocyte Count / Q000187:drug effects / Q000662:veterinary; D008297:Male; D009369:Neoplasms / Q000188:drug therapy / Q000662:veterinary*; D010976:Platelet Count / Q000187:drug effects / Q000662:veterinary; D011996:Records / Q000662:veterinary; D012189:Retrospective Studies
D004317:Doxorubicin